1. Home
  2. PARR vs ADPT Comparison

PARR vs ADPT Comparison

Compare PARR & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Par Pacific Holdings Inc.

PARR

Par Pacific Holdings Inc.

HOLD

Current Price

$52.53

Market Cap

2.9B

Sector

Energy

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$16.33

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PARR
ADPT
Founded
1984
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Integrated oil Companies
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
3.0B
IPO Year
2000
2019

Fundamental Metrics

Financial Performance
Metric
PARR
ADPT
Price
$52.53
$16.33
Analyst Decision
Buy
Strong Buy
Analyst Count
6
9
Target Price
$70.17
$17.78
AVG Volume (30 Days)
898.7K
2.2M
Earning Date
05-05-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
1313.56
63.89
EPS
1.10
N/A
Revenue
$2,443,066,000.00
$276,976,000.00
Revenue This Year
N/A
$3.98
Revenue Next Year
$3.78
$22.72
P/E Ratio
$48.62
N/A
Revenue Growth
30.99
54.77
52 Week Low
$26.41
$9.96
52 Week High
$70.39
$20.76

Technical Indicators

Market Signals
Indicator
PARR
ADPT
Relative Strength Index (RSI) 37.93 62.10
Support Level $33.67 $14.87
Resistance Level $59.08 $17.72
Average True Range (ATR) 2.37 1.39
MACD -0.22 0.18
Stochastic Oscillator 12.66 68.24

Price Performance

Historical Comparison
PARR
ADPT

About PARR Par Pacific Holdings Inc.

Par Pacific Holdings Inc is an oil and gas company that manages and maintains interests in energy and infrastructure businesses. The company has three reportable segments: Refining. Under its refining business, the company produces ultra-low-sulfur diesel, gasoline, jet fuel, marine fuel, LSFO, and other associated refined products. Its Retail includes operating licenses out brands to serve the retail consumer. Through the Logistics segment, crude shipments are delivered to the refineries, in addition to finished products that are exported. It generates maximum revenue from the Refining segment.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: